Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $26.60 Average PT from Analysts

Astria Therapeutics, Inc. (NASDAQ:ATXS) has received an average recommendation of “Buy” from the seven ratings firms that are covering the company, MarketBeat.com reports. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $26.60.

ATXS has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of Astria Therapeutics in a report on Tuesday, March 11th. JMP Securities assumed coverage on Astria Therapeutics in a research note on Friday, January 31st. They issued an “outperform” rating and a $26.00 price objective for the company. Citizens Jmp upgraded Astria Therapeutics to a “strong-buy” rating in a research note on Friday, January 31st. Finally, Wedbush reissued an “outperform” rating and issued a $28.00 price target (up from $27.00) on shares of Astria Therapeutics in a report on Wednesday, March 12th.

Astria Therapeutics Price Performance

NASDAQ ATXS opened at $5.17 on Wednesday. The business’s 50-day moving average is $5.56 and its 200 day moving average is $8.11. Astria Therapeutics has a 1 year low of $3.56 and a 1 year high of $12.92. The stock has a market capitalization of $291.76 million, a PE ratio of -2.47 and a beta of 0.68.

Astria Therapeutics (NASDAQ:ATXS) last announced its quarterly earnings data on Tuesday, March 11th. The biotechnology company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.01. As a group, equities research analysts anticipate that Astria Therapeutics will post -1.65 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ATXS. Fcpm Iii Services B.V. purchased a new stake in shares of Astria Therapeutics in the fourth quarter valued at $25,680,000. Vestal Point Capital LP increased its holdings in shares of Astria Therapeutics by 4.5% in the fourth quarter. Vestal Point Capital LP now owns 4,180,000 shares of the biotechnology company’s stock valued at $37,369,000 after purchasing an additional 180,000 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Astria Therapeutics during the fourth quarter worth about $707,000. Patient Square Capital LP increased its stake in shares of Astria Therapeutics by 166.5% in the fourth quarter. Patient Square Capital LP now owns 105,057 shares of the biotechnology company’s stock worth $939,000 after acquiring an additional 65,635 shares during the period. Finally, Voya Investment Management LLC raised its stake in shares of Astria Therapeutics by 367.4% during the 4th quarter. Voya Investment Management LLC now owns 71,708 shares of the biotechnology company’s stock valued at $641,000 after buying an additional 56,366 shares during the last quarter. 98.98% of the stock is owned by hedge funds and other institutional investors.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.